P. Roberts

发表

Lung Squamous Cell Carcinoma mRNA Expression Subtypes Are Reproducible, Clinically Important, and Correspond to Normal Cell Types

Christopher R. Cabanski, C. Perou, D. Hayes, 2010, Clinical Cancer Research.

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

J. Fletcher, G. Demetri, H. Joensuu, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.

A. D. Van den Abbeele, J. Fletcher, G. Demetri, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.

D. Tuveson, G. Demetri, H. Joensuu, 2001, The New England journal of medicine.

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

A. D. Van den Abbeele, S. Silverman, D. Tuveson, 2002, The New England journal of medicine.

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

C. Der, P. Roberts, C J Der, 2007, Oncogene.

Combined PI3K/mTOR and MEK Inhibition Provides Broad Antitumor Activity in Faithful Murine Cancer Models

James S. Duncan, C. Perou, David B. Darr, 2012, Clinical Cancer Research.

CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation.

C. Paweletz, G. Freeman, Kwok-Kin Wong, 2017, Cancer discovery.

Genetically engineered cancer models, but not xenografts, faithfully predict anticancer drug exposure in melanoma tumors.

N. Sharpless, P. Roberts, P. Dillon, 2012, The oncologist.

Uroplakin gene expression by normal and neoplastic human urothelium.

G. Hall, J. Southgate, P. Roberts, 1998, The American journal of pathology.

Chemotherapy and CDK4/6 Inhibitors: Unexpected Bedfellows

P. Roberts, E. Knudsen, A. Witkiewicz, 2020, Molecular Cancer Therapeutics.

The Influence of CYP3A5 Genotype on Dexamethasone Induction of CYP3A Activity in African Americans

P. Roberts, E. Schuetz, E. E. Williams, 2008, Drug Metabolism and Disposition.

Title: The Influence of CYP3A5 Genotype on Dexamethasone Induction of CYP3A Activity in

P. Roberts, E. Schuetz, E. E. Williams, 2008 .

CALL FOR PAPERS Novel Therapeutics in Renal Diseases CDK4/6 inhibition induces epithelial cell cycle arrest and ameliorates acute kidney injury

Kwok-Kin Wong, N. Sharpless, P. Roberts, 2022 .

Novel Therapeutics in Renal Diseases CDK 4 / 6 inhibition induces epithelial cell cycle arrest and ameliorates acute kidney injury

Kwok-Kin Wong, N. Sharpless, P. Roberts, 2014 .

Loss of cyclin-dependent kinase inhibitor genes and chromosome 9 karyotypic abnormalities in human bladder cancer cell lines.

J. Southgate, P. Roberts, P. Selby, 1995, British Journal of Cancer.

Prediction of lung cancer histological types by RT-qPCR gene expression in FFPE specimens.

Roy R. L. Bastien, C. Fan, C. Perou, 2013, The Journal of molecular diagnostics : JMD.

Alterations of LKB1 and KRAS and risk of brain metastasis: comprehensive characterization by mutation analysis, copy number, and gene expression in non-small-cell lung carcinoma.

D. Hayes, M. Wilkerson, Kwok-Kin Wong, 2014, Lung cancer.

Sialyl Tn antigen is an independent predictor of outcome in patients with gastric cancer

C. Haglund, O. Nilsson, S. Nordling, 1996, International journal of cancer.

Lung squamous cell carcinoma mRNA expression subtypes are reproducible , clinically important and correspond to different normal cell types

Christopher R. Cabanski, C. Perou, D. Hayes, 2010 .

Prognostic value of various staging and grading systems in proximal colon cancer.

Y. Collan, P. Roberts, M. Laato, 2002, The European journal of surgery = Acta chirurgica.

Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease.

B. Eisenberg, P. Roberts, 2002, European journal of cancer.

Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial

T. Owonikoko, P. Roberts, J. Hamm, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Comparison of a new tumour marker, CA 199TM, with a-fetoprotein and carcinoembryonic antigen in patients with upper gastrointestinal diseases

C. Haglund, O. Mäkelä, P. Roberts, 2004 .

Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?

M. Socinski, C. Der, T. Stinchcombe, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sialyl Tn Is a Frequently Expressed Antigen in Colorectal Cancer: No Correlation with Patient Prognosis

S. Nordling, M. Lundin, C. Haglund, 1999, Oncology.

A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response

Andrew L. Kung, Matthew D. Wilkerson, Michael D. Cameron, 2012, Nature.

Tumour marker CA 125 in patients with digestive tract malignancies.

C. Haglund, P. Roberts, H. Jalanko, 1991, Scandinavian journal of clinical and laboratory investigation.

Tumour markers in pancreatic cancer.

C. Haglund, P. Roberts, P. Kuusela, 1989, Annales chirurgiae et gynaecologiae.

Title: Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically-important and correspond to different normal cell types

Christopher R. Cabanski, C. Perou, D. Hayes, 2010 .

Tissue expression of the tumour associated antigen CA242 in benign and malignant pancreatic lesions. A comparison with CA 50 and CA 19-9.

S. Nordling, C. Haglund, P. Roberts, 1989, British Journal of Cancer.

N;-3 and n;-6 polyunsaturated fatty acids induce cytostasis in human urothelial cells independent of p53 gene function.

J. Southgate, P. Roberts, L. Trejdosiewicz, 2000, Journal of lipid research.

Prognostic value of immunohistochemical expression of p53 in patients with pancreatic cancer.

S. Nordling, C. Haglund, J. Lundin, 1996, Oncology.

Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial.

T. Owonikoko, P. Roberts, J. Hamm, 2019 .

Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer.

C. Haglund, O. Mäkelä, C. Haglund, 1986, British Journal of Cancer.

A retrospective analysis of submissions, acceptance rate, open peer review operations, and prepublication bias of the multidisciplinary open access journal Head & Face Medicine

C. Haglund, C. Haglund, P. Roberts, 2006, PLoS biology.

Comparison of CA-50, a new tumour marker, with carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP) in patients with gastrointestinal diseases.

C. Haglund, P. Roberts, H. Jalanko, 1987, British Journal of Cancer.

Comparison of CA 19-9 and carcinoembryonic antigen (CEA) levels in the serum of patients with colorectal diseases.

O. Mäkelä, P. Roberts, J. Mecklin, 1984, British Journal of Cancer.

Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancer

T. Owonikoko, P. Roberts, L. Hart, 2021, Cancer Chemotherapy and Pharmacology.

Ki-67 immunoreactivity, ploidy and S-phase fraction as prognostic factors in patients with gastric carcinoma.

S. Nordling, C. Haglund, P. Roberts, 1996, Oncology.

Prognostic significance of serum CA 242 in pancreatic cancer. A comparison with CA 19-9.

C. Haglund, J. Lundin, P. Roberts, 1995, Anticancer research.

The prognostic value of preoperative serum levels of CA 19-9 and CEA in patients with pancreatic cancer.

C. Haglund, J. Lundin, P. Roberts, 1994, British Journal of Cancer.

Non-specific antiviral activity of antisense molecules targeted to the E1 region of human papillomavirus.

P. Roberts, D. Szymkowski, J. Bishop, 2000, Antiviral research.

Expression of laminin in benign and malignant sclerosing lesions of extrahepatic bile ducts.

S. Nordling, C. Haglund, P. Roberts, 1989, Journal of clinical pathology.

Gastrointestinal cancer-associated antigen CA 19-9 in histological specimens of pancreatic tumours and pancreatitis.

S. Nordling, C. Haglund, P. Roberts, 1986, British Journal of Cancer.

Disease and Urine of Patients with Malignant Pancreatic and Biliary Fragment of Human Choriogonadotropin in the Serum β Core Subunit of Human Choriogonadotropin and β Elevation of Free Updated

C. Haglund, P. Roberts, H. Alfthan, 2006 .

Elevation of free beta subunit of human choriogonadotropin and core beta fragment of human choriogonadotropin in the serum and urine of patients with malignant pancreatic and biliary disease.

C. Haglund, C. Haglund, P. Roberts, 1992, Cancer research.

Tissue expression of the tumor marker CA 50 in benign and malignant pancreatic lesions. A comparison with CA 19‐9

C. Haglund, S. Nordling, P. Roberts, 1986, International journal of cancer.

Difference in tissue expression of tumour markers CA 19-9 and CA 50 in hepatocellular carcinoma and cholangiocarcinoma.

S. Nordling, C. Haglund, P. Roberts, 1991, British Journal of Cancer.

Serum ca 50 as a tumor marker in pancreatic cancer: A comparison with CA 19‐9

C. Haglund, P. Roberts, H. Jalanko, 1987, International journal of cancer.

Tumour markers CA 19-9 and CA 50 in digestive tract malignancies.

C. Haglund, P. Roberts, H. Jalanko, 1992, Scandinavian journal of gastroenterology.

MMP-1 expression has an independent prognostic value in breast cancer

T. Vahlberg, P. Roberts, P. Boström, 2011, BMC Cancer.

Rho Family GTPase Modification and Dependence on CAAX Motif-signaled Posttranslational Modification*

C. Der, N. Mitin, P. Roberts, 2008, Journal of Biological Chemistry.

Targeting Ras for Anticancer Drug Discovery

P. M. Campbell, C. Der, J. Yeh, 2010 .

Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy.

Charles M. Perou, Kwok-Kin Wong, William C. Zamboni, 2012, Journal of the National Cancer Institute.

Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression

P. Roberts, J. Bisi, F. Tavares, 2016, Molecular Cancer Therapeutics.

CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy

T. Owonikoko, P. Roberts, K. Dragnev, 2020, Journal for ImmunoTherapy of Cancer.

Trilaciclib (G1T28): A cyclin dependent kinase 4/6 inhibitor, in combination with etoposide and carboplatin (EP) for extensive stage small cell lung cancer (ES-SCLC)—Phase 1b results.

G. Shapiro, T. Owonikoko, M. Thomas, 2017 .

Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion

N. Sharpless, P. Roberts, J. Bisi, 2017, Science Translational Medicine.

First-in-human Phase 1 safety, PK, and PD study of the CDK4/6 inhibitor G1T28.

P. Roberts, J. Bisi, J. Strum, 2015 .

Abstract CT151: G1T28, a cyclin dependent kinase 4/6 inhibitor, in combination with etoposide and carboplatin for extensive stage small cell lung cancer (ES-SCLC): preliminary results

M. Thomas, P. Roberts, V. Priego, 2016 .

Targeting Ras and Rho Family GTPases for the Treatment of Cancer Through Inhibition of CAAX-Signaled Modifications and the ERK MAPK Pathway.

P. Roberts, 2007 .

Ras Stories: The State of the Art

C. Der, P. Roberts, 2006 .

Increased proliferation activity measured by immunoreactive Ki67 is associated with survival improvement in rectal/recto sigmoid cancer.

T. Vahlberg, P. Roberts, E. Salminen, 2005, World journal of gastroenterology.

Predicting Drug Responsiveness in Human Cancers Using Genetically Engineered Mice

C. Perou, M. Cheang, Wei Zhao, 2013, Clinical Cancer Research.

KRAS mutation: should we test for it, and does it matter?

T. Stinchcombe, P. Roberts, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Management of malignant gastrointestinal stromal tumours.

G. Demetri, H. Joensuu, P. Roberts, 2002, The Lancet. Oncology.

Abstract 5628: Trilaciclib (G1T28), a CDK4/6 inhibitor, enhances the efficacy of combination chemotherapy and immune checkpoint inhibitor treatment in preclinical models

P. Roberts, J. Strum, J. Sorrentino, 2017 .

Independent prognostic value of preoperative serum markers CA 242, specific tissue polypeptide antigen and human chorionic gonadotrophin beta, but not of carcinoembryonic antigen or tissue polypeptide antigen in colorectal cancer.

C. Haglund, J. Lundin, P. Roberts, 1996, British Journal of Cancer.

Clinical use of crizotinib for the treatment of non-small cell lung cancer

P. Roberts, 2013, Biologics : targets & therapy.

Tumour-associated trypsin inhibitor, TATI, in patients with pancreatic cancer, pancreatitis and benign biliary diseases.

S. Nordling, C. Haglund, P. Roberts, 1986, British Journal of Cancer.

Kinase M utations a nd I matinib R esponse i n P atients W ith Metastatic G astrointestinal S tromal T umor

J. Fletcher, G. Demetri, S. Singer, 2003 .

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.

A. D. Van den Abbeele, J. Fletcher, G. Demetri, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors

P. Roberts, J. Bisi, F. Tavares, 2017, Oncotarget.

Ki-67, ploidy and S-phase fraction as prognostic factors in gastric cancer.

S. Nordling, C. Haglund, P. Roberts, 1997, Anticancer research.

The Significance of Tumor Markers for Proliferation and Apoptosis in Predicting Survival in Colorectal Cancer

Y. Collan, P. Roberts, M. Laato, 2005, Diseases of the colon and rectum.

Pre-operative serum levels of CA 242 and CEA predict outcome in colorectal cancer.

C. Haglund, C. Haglund, J. Lundin, 1996, European journal of cancer.

A risk score for predicting outcome in patients with gastric cancer, based on stage, sialyl‐Tn immunoreactivity and ploidy—a multivariate analysis

S. Nordling, C. Haglund, J. Lundin, 1996, International journal of cancer.

Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-mutant Pancreatic Cancer.

E. Petricoin, C. Der, P. Roberts, 2022, Cancer research.

Differences in serum tumor markers between colon and rectal cancer

C. Haglund, P. Roberts, M. Carpelan-Holmström, 1996, Diseases of the colon and rectum.

Serum CA 242 and CEA detect different patients with recurrent colorectal cancer.

C. Haglund, P. Roberts, H. Järvinen, 1996, Anticancer research.

Prognostic significance of matrix metalloproteinases‐1, ‐2, ‐7 and ‐13 and tissue inhibitors of metalloproteinases‐1, ‐2, ‐3 and ‐4 in colorectal cancer

Y. Collan, P. Roberts, M. Laato, 2007, International journal of cancer.

Expression of p53 protein as a prognostic factor in patients with gastric cancer.

S. Nordling, C. Haglund, J. Lundin, 1996, European journal of cancer.

Posttranslational lipid modification of Rho family small GTPases.

C. Der, N. Mitin, P. Roberts, 2012, Methods in molecular biology.

CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA.

C. Haglund, J. Lundin, P. Roberts, 1994, British Journal of Cancer.

Tumour markers in pancreatic cancer.

C. Haglund, P. Roberts, H. Jalanko, 1986, Scandinavian journal of gastroenterology. Supplement.

Cancer Therapy : Preclinical Combined PI 3 K / mTOR and MEK Inhibition Provides Broad Antitumor Activity in Faithful Murine Cancer Models

James S. Duncan, C. Perou, David B. Darr, 2012 .

Expression of laminin in pancreatic neoplasms and in chronic pancreatitis

S. Nordling, C. Haglund, P. Roberts, 1984, The American journal of surgical pathology.

Prognostic value of Ki-67 expression, ploidy and S-phase fraction in patients with pancreatic cancer.

C. Haglund, S. Nordling, C. Haglund, 1995, Anticancer research.

Differences in Serum Tumor Markers Be tween Colon and Rectal Cancer Comparison of CA 242 and Carcinoembryonic Antigen

C. Haglund, P. Roberts, M. Carpelan-Holmström, 2005 .

The influence of training level and surgical experience on survival in colorectal cancer

Y. Collan, P. Roberts, M. Laato, 2004, Langenbeck's Archives of Surgery.

A prognostic value of CA 19-9 but not of CEA in patients with gastric cancer.

C. Haglund, J. Lundin, P. Roberts, 1995, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Preoperative serum levels of CEA and CA 242 in colorectal cancer.

C. Haglund, P. Roberts, H. Järvinen, 1995, British Journal of Cancer.

Tumour markers in colorectal cancer.

P. Roberts, 1988, Scandinavian journal of gastroenterology. Supplement.

Tissue expression of the tumour associated antigen CA242 in benign and malignant pancreatic lesions. A comparison with CA 50 and CA 19-9.

C. Haglund, S. Nordling, P. Roberts, 1989, British Journal of Cancer.

Predicting Drug Responsiveness in Human Cancers Using Genetically Engineered Mice

Jason I. Herschkowitz, C. Perou, M. Cheang, 2013, Clinical Cancer Research.

Alterations of LKB1 and KRAS and risk of brain metastasis: comprehensive characterization by mutation analysis, copy number, and gene expression in non-small-cell lung carcinoma.

D. Hayes, M. Wilkerson, L. Thorne, 2014, Lung cancer.

Lung Squamous Cell Carcinoma mRNA Expression Subtypes Are Reproducible, Clinically Important, and Correspond to Normal Cell Types

Christopher R. Cabanski, C. Perou, D. Hayes, 2010, Clinical Cancer Research.

Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-mutant Pancreatic Cancer.

E. Petricoin, C. Der, P. Roberts, 2022, Cancer research.

Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression

P. Roberts, J. Bisi, J. Strum, 2016, Molecular Cancer Therapeutics.